FindTrial
Sign In

Effect of stem cells presence in two major categories of Breast Cancer - A comparison.

Cancer stem cell marker CD133 in Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer– An immunohistochemical study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/01/061651
Enrollment
50
Registered
2024-01-19
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Maulana Azad Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Histopathologically confirmed cases of Infiltrating Ductal Carcinoma (no special type NST)

Exclusion criteria

Exclusion criteria: Patients with prior neoadjuvant chemotherapy or radiation therapy

Design outcomes

Primary

MeasureTime frame
The expression of CD133 in triple negative breast cancers (TNBC) versus non triple negative breast cancers (NTNBC)Timepoint: Baseline—

Secondary

MeasureTime frame
The association of CD133 with histological grade, clinical stage & proliferation index (ki67) in triple negative breast cancers (TNBC) & non triple negative breast cancers (NTNBC)Timepoint: Baseline—

Countries

India

Contacts

Public ContactDr Pushpit Gupta

Maulana Azad Medical College

drreenat@yahoo.com9711972630

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026